|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 194.4 USD | +2.03% |
|
-1.92% | -24.88% |
| Apr. 19 | Needham Adjusts Price Target on Biogen to $294 From $300 | MT |
| Apr. 19 | BMO Capital Adjusts Price Target on Biogen to $260 From $285, Outperform Rating Kept | MT |
May 3 (Reuters) - Biogen Inc reported a quarterly profit on Tuesday that fell 26% as sales of its blockbuster multiple sclerosis drug Tecfidera continued to be pressured by cheaper versions of the treatment. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)
| 1st Jan change | Capi. | |
|---|---|---|
| -24.88% | 27.69B | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B | |
| +1.05% | 7.51B |
BIOGEN INC. 
